Cancer Specialist (Oncologist), Hematology and Oncology Specialist
Dr. George is a physician scientist with a focus on gastrointestinal malignancies and new cancer therapy development. As director of the GI Oncology Program at the University of Florida, Dr. George helps to oversee the multidisciplinary treatment of patients with GI malignancies. He also develops and tests new cancer treatments as the director of Experimental Therapeutics through clinical trials leveraging advancements in precision oncology and immunotherapy across a variety of cancer types. He previously served as chair of the Medical Advisory Board to the State of Florida Department of Health and the Screen for Life Colorectal Cancer Screening Program, which targets historically underserved populations. He also completed a 10 year term as the gubernatorial-appointed chair of the Florida Cancer Control and Research Advisory Council, which advises the legislature, Department of Health, and state surgeon general on all cancer related matters and policy. He currently serves as the Interim Director of the UF Health Cancer Institute. As a National Cancer Institute funded clinical investigator and through national leadership in several clinical trial groups and research organizations, Dr. George is both advancing the field and supporting the next generation of physician scientists. He is a member of the medical honor society Alpha Omega Alpha, the American Society of Clinical Oncology, the American Association for Cancer Research, and numerous cancer research groups.
Please note: Some physicians and practices might not accept a specific insurance plan. Our list is also subject to change, and sometimes that change is not yet reflected in this list. Please contact the practice to confirm that your insurance is accepted. A representative will be happy to assist you.
See all insurancesResearchers want to learn if patritumab deruxtecan (MK-1022) can treat certain gastrointestinal (GI) cancers. The GI cancers being studied are advanced (the cancer has spread to other parts of the body). The goals of this study are to learn: About…
This is a Phase I open label, dose-escalation study of intravenous (IV) infusion of ONC-841 as a single agent in patients with advanced/metastatic solid tumors. The study will evaluate seven dose levels of ONC-841 starting from 0.03 mg/kg to 30…
High blood pressure (hypertension) is a known side effect of the treatment with fruquintinib. Current research does not provide a clear answer whether minority groups such as Black/African American and/or Hispanic/Latino with refractory metastatic…
December 11, 2023
For many patients diagnosed with cancer, the burden extends well beyond the clinic walls, as out-of-pocket medical costs and travel expenses add up. Many…
College of Medicine, UF Health Cancer Institute, +2 more
July 13, 2023
The University of Florida Health Cancer Center has appointed two accomplished oncologists to key executive leadership roles, positioning the center to reach…
Department of Urology, +4 more
